title: Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey.
authors.affiliation: Department of Urology, Scientific Institute San Raffaele, Milan, Italy. Electronic address: montorsi.francesco@hsr.it.
authors.forename: Francesco
authors.initials: F
authors.lastname: Montorsi
authors.affiliation: Astellas Pharma Europe Ltd., Chertsey, Surrey, UK.
authors.forename: Philippa
authors.initials: P
authors.lastname: Tomlinson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005060:Europe; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D057240:Patient Preference; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone